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This March, Public Health England will officially launch a routine whole-genome 
sequencing service for mycobacterial infections, becoming the first national administration in 
the world to do so. The implications are profound with many of the methods that have become 
commonplace around the world being replaced. From now on, when mycobacterial cultures 
are referred to reference facilities, comprehensive whole-genome sequencing-based reports 
will be returned within 5–7 days. Reports will detail mycobacterial species, and predict drug 
susceptibility and genetic relatedness for the Mycobacterium tuberculosis complex. The 
changes have the potential to affect how clinical decisions are made, and how tuberculosis 
control is done. Other countries are already preparing for a similar transition and will be 
watching events in England carefully. If all goes well, we could soon see widespread 
international adoption of similar procedures.  
The costs of whole-genome sequencing are expected to be covered by phasing out 
tests currently on offer.1 These include 24-locus mycobacterial interspersed repetitive units–
variable number of tandem repeat (MIRU–VNTR) typing for which whole-genome sequencing 
has been shown to have a greater specificity, promising savings to the public health budget 
by avoiding unnecessary contact investigations, and improved disease control by virtue of 
more focused deployment of resources.2 They also include the various line-probe assays on 
the market, which target short nucleotide sequences that can easily be identified in whole-
genome sequencing data. Because genomic analysis allows the detection of many rarer 
mutations alongside the dominant ones, an increase in sensitivity over PCR-based assays is 
expected.3  
Whole-genome sequencing is the logical conclusion of a shift away from culture 
methods that started with the arrival of PCR-based technologies in diagnostic microbiology. 
The best known direct-from-sample test is the MTB/RIF Xpert, which can identify the M 
tuberculosis complex directly from clinical samples and flag multidrug-resistant disease.4 
Although whole-genome sequencing provides more complete data than this assay, culture 
remains a prerequisite to sequencing. However, direct whole-genome sequencing from clinical 
samples is looking promising and if technologies such as strand sequencing evolve as 
expected, there is the prospect of them taking over as first-line, definitive, culture-free 
assays.5 Price permitting, this would complete the shift away from culture.  
The implications for clinical management are already far reaching. Clinicians will start 
receiving interpreted diagnostic reports based on genomic mutations, eventually cross-
correlated to minimum inhibitory concentrations. If received within a useful timeframe, this 
information could supplant empirical therapy, with treatment tailored to the susceptibility of the 
organism at initiation. It could also allow routine decisions to be made about offering higher 
doses to patients whose strains harbour mutations that cause only low-grade resistance (eg, 
upstream fabG1/inhA mutations for isoniazid).6 The precision of these whole-genome 
sequencing-based data, which are often more reproducible than phenotypic data,3 could also 
lead to a reconsideration of the need for a fourth drug as part of first-line therapy, often 
considered an insurance policy against undetected resistance.7 Because all molecular drug 
susceptibility predictions will be reported concurrently, and eventually for up to 15 drugs, the 
results of whole-genome sequencing will present an opportunity to design bespoke treatment 
regimens early on, helping to minimise further amplification in the most resistant cases.  
From the point-of-view of tuberculosis control, whole-genome sequencing will report 
evolutionary relationships between isolates with unprecedented granularity. Building on 
population studies that have been done in the past, routine roll-out will help to give the most 
precise nationwide insights to date into the number of cases transmitted locally and their 
transmission dynamics.8,9 This development is expected to inform control measures at local 
levels and policies at a national level.  
The downstream effects of these advances on international health are keenly 
anticipated. If sequencing platforms progress as promised,5 portable (so-called lab-in-a-bag) 
technologies could help deliver these same benefits to where the need is greatest—to low-
income, high-incidence settings, directly from clinical samples whilst the patient waits. Over 
and above the MTB/ RIF Xpert, whole-genome sequencing platforms could provide near to 
complete data to inform clinical decision making, indicating which drug to give, not just which 
to avoid. This month’s launch therefore marks only the very beginning of a new era in 
mycobacteriology. Whether other organisms will follow suit remains unclear. M tuberculosis 
is, after all, the organism among all bacterial pathogens with the greatest need and the 
greatest potential to benefit from whole-genome sequencing-based diagnostics. M 
tuberculosis killed more people in 2015 than any other single pathogen, and yet delay to full 
microbiological diagnosis remains at weeks, and in many high-incidence, low-income settings 
is not achieved at all.10 A National Center for Biotechnology Information search shows that 
the number of publically available M tuberculosis sequences already exceeds 25 000, but 
much is still to be learnt. As the number of sequences from routine diagnostics accumulate, 
the pace of change will only accelerate. In this respect, at least, we live in exciting times.  
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